Preferred ANA screening test for systemic autoimmune rheumatic disease (ie, connective tissue disease).
Semi-Quantitative Indirect Fluorescent Antibody
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Less than 1:80
Presence of antinuclear antibodies (ANA) is a hallmark feature of systemic autoimmune rheumatic diseases (SARD). ANA lacks diagnostic specificity and is associated with a variety of diseases (cancers, autoimmune, infectious, and inflammatory conditions) and may also occur in healthy individuals in varying prevalence. The lack of diagnostic specificity requires confirmation of positive ANA by more-specific serologic tests. Diagnosis may be aided by the pattern(s) observed.
Negative results do not necessarily rule out SARD.
No compliance statements are in use for this test.
ANA are determined by indirect fluorescence assay (IFA) using HEp-2 substrate and IgG-specific conjugate at a screening dilution of 1:80. If positive, patterns reported include homogeneous, speckled, centromere, nucleolar, nuclear dots, or cytoplasmic. All positive results are reported with endpoint titers, at no additional charge.
|Component Test Code*||Component Chart Name||LOINC|
|3000090||Antinuclear Antibody (ANA), HEp-2, IgG||21424-7|
|3000096||ANA Interpretive Comment||49311-4|
- Antinuclear Antibodies
- Antinuclear Antibody
- Fluorescent Antinuclear Antibodies